Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) gefitinib (Iressa), erlotinib (Tarceva) is a selective tyrosine kinas
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) gefitinib (Iressa), erlotinib (Tarceva) is a selective tyrosine kinase inhibitor, has become the advanced non second-line platinum based treatment failure in small cell lung cancer and three line therapy.
Preliminary study shows that the mutation rate of EGFR and gefitinib treatment advantage population which patients, female, adenocarcinoma, non smoker and Asian EGFR mutation rate higher than that of the male, non cancer, smokers and non Asian patients, so as to reveal the NSCLC of gefitinib sensitive molecular mechanism. A large number of clinical research results show that the EGFR mutation positive patients on gefitinib efficiency was 50% ~ 80%, and the wild type were efficiency is only 15%, so screening may benefit population can greatly save medical cost and realize the individualized targeted therapy. Therefore, EGFR mutation has become an important molecular marker for efficacy prediction.
The current gold standard for EGFR mutation is DNA sequencing, but the time-consuming, high cost, low sensitivity, detection of more sensitive molecular detection platform and the establishment of the EGFR mutation in peripheral blood will help to realize the individualized molecular targeted therapy.
We used DHPLC to analyze the mutations of EGFR19 and exon 21 in non small cell lung cancer (EGFR), and preliminarily confirmed that DHPLC can be used as a primary screening method for the detection of mutations in non-small cell lung cancer. The plasma free DNA EGFR mutation has a high consistency with the tumor tissue, and can be used as an alternative to detect EGFR mutation in tumor tissues.
Requirements: after surgery or needle aspiration biopsy tissue wax or pathological white film 5 - 10um about 10, or the extraction of venous blood 20ml, the report of the work of the seven single.